Bicocca Open Archive

Logo unimib boa
ZAMBELLI, ALBERTO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 1.489
EU - Europa 1.098
AS - Asia 907
SA - Sud America 81
AF - Africa 17
Continente sconosciuto - Info sul continente non disponibili 3
OC - Oceania 1
Totale 3.596
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.461
RU - Federazione Russa 338
HK - Hong Kong 319
SG - Singapore 307
IT - Italia 197
DE - Germania 186
CN - Cina 125
SE - Svezia 83
BR - Brasile 75
IE - Irlanda 75
ID - Indonesia 70
UA - Ucraina 55
AT - Austria 44
NL - Olanda 35
VN - Vietnam 35
GB - Regno Unito 31
CA - Canada 24
FI - Finlandia 18
FR - Francia 13
TR - Turchia 13
ZA - Sudafrica 11
DK - Danimarca 9
PH - Filippine 5
AZ - Azerbaigian 4
CH - Svizzera 4
IN - India 4
MX - Messico 4
EU - Europa 3
IR - Iran 3
MA - Marocco 3
AM - Armenia 2
AR - Argentina 2
BE - Belgio 2
CO - Colombia 2
ET - Etiopia 2
IQ - Iraq 2
JP - Giappone 2
LK - Sri Lanka 2
LV - Lettonia 2
RO - Romania 2
TH - Thailandia 2
TW - Taiwan 2
BD - Bangladesh 1
BH - Bahrain 1
CZ - Repubblica Ceca 1
EC - Ecuador 1
EE - Estonia 1
GA - Gabon 1
HU - Ungheria 1
IL - Israele 1
KW - Kuwait 1
KZ - Kazakistan 1
NP - Nepal 1
NZ - Nuova Zelanda 1
OM - Oman 1
PK - Pakistan 1
PL - Polonia 1
TM - Turkmenistan 1
UY - Uruguay 1
UZ - Uzbekistan 1
Totale 3.596
Salva come PNG Salva come JPEG
Città #
Hong Kong 319
Ann Arbor 258
Singapore 180
Ashburn 148
Fairfield 126
Woodbridge 107
Chandler 94
Frankfurt am Main 77
Dublin 74
Jakarta 67
Seattle 67
Wilmington 60
Milan 56
Nuremberg 54
Houston 53
Dearborn 38
Cambridge 36
Jacksonville 36
Moscow 35
Santa Clara 33
Princeton 30
New York 29
Vienna 24
Dong Ket 21
Shanghai 21
Altamura 15
Lawrence 14
Los Angeles 12
Guangzhou 11
Kocaeli 11
Nanjing 10
Lissone 9
Ottawa 9
San Diego 9
Boardman 8
Wuxi 8
Arezzo 7
Bari 7
Lachine 7
Lappeenranta 7
Council Bluffs 6
Gainesville 6
Hangzhou 6
Shenzhen 6
Silver Spring 6
Columbus 5
Hebei 5
Toronto 5
Andover 4
Baku 4
Helsinki 4
Mexico City 4
Padova 4
Rome 4
Shenyang 4
Verona 4
Bergamo 3
Changsha 3
Chicago 3
Falkenstein 3
Jiaxing 3
Jinan 3
London 3
Tianjin 3
Addis Ababa 2
Amsterdam 2
Bangkok 2
Beijing 2
Belo Horizonte 2
Bologna 2
Brembate di Sopra 2
Brussels 2
Casalecchio di Reno 2
Catania 2
Chiuduno 2
Colombo 2
Curitiba 2
Edina 2
Edmonton 2
Florence 2
Kiev 2
Lucca 2
Mountain View 2
Munich 2
Naples 2
Newark 2
Pavia 2
Riga 2
Rio de Janeiro 2
Rotherham 2
San Marzano Oliveto 2
Stockholm 2
São Gonçalo 2
Taizhou 2
Tarlac City 2
Trieste 2
Turin 2
Yerevan 2
Zanjan 2
Zhengzhou 2
Totale 2.360
Salva come PNG Salva come JPEG
Nome #
Trastuzumab for HER2+ metastatic breast cancer in clinical practice: Cardiotoxicity and overall survival 238
Management and Survival of Pleural Mesothelioma: A Record Linkage Study 233
Antitumour activity of trabectedin in myelodysplastic/myeloproliferative neoplasms 226
Resistance to platinum-based chemotherapy is associated with epithelial to mesenchymal transition in epithelial ovarian cancer 174
Effectiveness of trastuzumab in first-line her2+ metastatic breast cancer after failure in adjuvant setting: A controlled cohort study 173
Long term survival of HER2-positive early breast cancer treated with trastuzumab-based adjuvant regimen: a large cohort study from clinical practice. 171
Trastuzumab-related cardiotoxicity in early breast cancer: A cohort study 162
Profiling cancer gene mutations in longitudinal epithelial ovarian cancer biopsies by targeted next-generation sequencing: a retrospective study 148
Erratum: Everolimus (EVE) and exemestane (EXE) in patients with advanced breast cancer aged ≥ 65 years: New lessons for clinical practice from the EVA study (Oncotarget (2018) 9 (31877-31887) DOI: 10.18632/oncotarget.25874) 127
Correction: Everolimus (Eve) and exemestane (EXE) in patients with advanced breast cancer aged ≥ 65 years: New lessons for clinical practice from the EVA study (Oncotarget (2018) 9:77 (34639-34640) DOI: 10.18632/oncotarget.25874) 122
Is There Still a Role for Endocrine Therapy Alone in HR+/HER2- Advanced Breast Cancer Patients? Results from the Analysis of Two Data Sets of Patients Treated with High-Dose Fulvestrant as First-Line Therapy in the Real-World Setting: The EVA and GIM-13 AMBRA Studies 119
Efficacy and safety of Everolimus and Exemestane in hormone-receptor positive (HR+) human-epidermal-growth-factor negative (HER2−) advanced breast cancer patients: New insights beyond clinical trials. The EVA study 82
Everolimus (EVE) and exemestane (EXE) in patients with advanced breast cancer aged ≥ 65 years: New lessons for clinical practice from the EVA study 81
Remodelling of the Ca2+ signalling machinery in endothelial progenitor cells isolated from breast cancer patients 70
Two Missense Variants Detected in Breast Cancer Probands Preventing BRCA2-PALB2 Protein Interaction 53
Charting the Course in Sequencing Antibody-Drug Conjugates in Breast Cancer 48
A cost-consequence analysis of adding pertuzumab to the neoadjuvant combination therapy in HER2-positive high-risk early breast cancer in Italy 47
Clinical Outcomes of HER2-Negative Metastatic Breast Cancer Patients in Italy in the Last Decade: Results of the GIM 13-AMBRA Study 45
Characterization of long COVID temporal sub-phenotypes by distributed representation learning from electronic health record data: a cohort study 35
Serum thymidine kinase activity in patients with HR-positive/HER2-negative advanced breast cancer treated with ribociclib plus letrozole: Results from the prospective BioItaLEE trial 34
Controversial topics in metastatic HR+/HER2- breast cancer: Guiding treatment by a modified Delphi approach 31
Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer 30
Real-world use of multigene signatures in early breast cancer: differences to clinical trials 28
Safety and Efficacy of Ribociclib in Combination with Letrozole in Patients with HR+, HER2- Advanced Breast Cancer: Results from the Italian Subpopulation of Phase 3b CompLEEment-1 Study 27
Fine-Tuning Adjuvant Endocrine Therapy for Early-Stage Breast Cancer: An Expert Consensus on Open Issues for Future Research 27
Empowerment, Pain Control, and Quality of Life Improvement in Early Triple-Negative Breast Cancer Patients through Pain Neuroscience Education: A Prospective Cohort Pilot Study Protocol (EMPOWER Trial) 26
Definition of High-Risk Early Hormone-Positive HER2-Negative Breast Cancer: A Consensus Review 26
Bone-Active Drugs in Pre-Menopausal Women with Breast Cancer Under Hormone Deprivation Therapies 26
Cyclin-dependent kinase 2 (CDK2) inhibitors and others novel CDK inhibitors (CDKi) in breast cancer: clinical trials, current impact, and future directions 25
Optimizing abemaciclib-induced diarrhea management in patients with breast cancer: a pragmatic 2-group study using a postbiotic microbiota stabilizer 25
Prognostic significance of HER2-low status in HR-positive/HER2-negative advanced breast cancer treated with CDK4/6 inhibitors 24
Parp-inhibitors in the therapeutic landscape of breast cancer patients with BRCA1 and BRCA2 pathogenic germline variants: An Italian consensus paper and critical review 24
Follow-up of early breast cancer in a public health system: A 2024 AIGOM consensus project 24
Common Misconceptions about Diet and Breast Cancer: An Unclear Issue to Dispel 23
International comparisons of laboratory values from the 4CE collaborative to predict COVID-19 mortality 22
Risks of breast and ovarian cancer for women harboring pathogenic missense variants in BRCA1 and BRCA2 compared with those harboring protein truncating variants 22
Deep Neural Network Integrated into Network-Based Stratification (D3NS): A Method to Uncover Cancer Subtypes from Somatic Mutations 22
The Impact of Different Patterns of Residual Disease on Long-Term Oncological Outcomes in Breast Cancer Patients Treated with Neo-Adjuvant Chemotherapy 22
PONDx: real-life utilization and decision impact of the 21-gene assay on clinical practice in Italy 22
Denosumab improves trabecular bone score in relationship with decrease in fracture risk of women exposed to aromatase inhibitors 22
Everolimus plus aromatase inhibitors as maintenance therapy after first-line chemotherapy: Final results of the phase III randomised MAIN-A (MAINtenance Afinitor) trial 21
Digital innovations in breast cancer care: exploring the potential and challenges of digital therapeutics and clinical decision support systems 21
Monitoring changing patterns in HER2 addiction by liquid biopsy in advanced breast cancer patients 21
Correction to: Denosumab improves trabecular bone score in relationship with decrease in fracture risk of women exposed to aromatase inhibitors (Journal of Endocrinological Investigation, (2023), 47, 2, (433-442), 10.1007/s40618-023-02174-5) 21
Platinum-based chemotherapy and PARP inhibitors for patients with a germline BRCA pathogenic variant and advanced breast cancer (LATER-BC): retrospective multicentric analysis of post-progression treatments 20
Corrigendum to “Prevalence of treatment-related adverse events (TRAEs) with antibody-drug conjugates in metastatic breast cancer patients: A systematic review and meta-analysis” [Crit. Rev. Oncol./Hematol. 204 (2024) 104527](S1040842824002701)(10.1016/j.critrevonc.2024.104527) 20
Sentinel lymph node biopsy versus axillary lymph node dissection in breast cancer patients undergoing mastectomy with one to two metastatic sentinel lymph nodes: sub-analysis of the SINODAR-ONE multicentre randomized clinical trial and reopening of enrolment 20
From seaside to bedside: Current evidence and future perspectives in the treatment of breast cancer using marine compounds 19
Controversies and Opportunities in the Clinical Daily Use of the 21-Gene Assay for Prognostication and Prediction of Chemotherapy Benefit in HR+/HER2- Early Breast Cancer 19
COVID-19 Sequelae and the Host Pro-Inflammatory Response: An Analysis From the OnCovid Registry 18
Empowering beyond Pain: Pain Neuroscience Education Interventions in Breast Cancer Survivorship Care 18
Hereditary Cancer Syndromes: A Comprehensive Review with a Visual Tool 18
Unlocking the Potential of Circulating miRNAs in the Breast Cancer Neoadjuvant Setting: A Systematic Review and Meta-Analysis 18
Association of tumor-infiltrating lymphocytes with recurrence score in hormone receptor-positive/HER2-negative breast cancer: Analysis of four prospective studies 18
Outcomes of the SARS-CoV-2 omicron (B.1.1.529) variant outbreak among vaccinated and unvaccinated patients with cancer in Europe: results from the retrospective, multicentre, OnCovid registry study 18
Prevalence of treatment-related adverse events (TRAEs) with antibody-drug conjugates in metastatic breast cancer patients: A systematic review and meta-analysis 18
Analysis of Italian BRCA1/2 Pathogenic Variants Identifies a Private Spectrum in the Population from the Bergamo Province in Northern Italy 18
Risk-Based Therapeutic Strategies for HER2-Positive Early Breast Cancer: A Consensus Paper 18
Multinational characterization of neurological phenotypes in patients hospitalized with COVID-19 17
BRCA Testing for Patients Treated in Italy: A National Survey of Breast Centers Associated with Senonetwork 17
Erratum: Risks of breast and ovarian cancer for women harboring pathogenic missense variants in BRCA1 and BRCA2 compared with those harboring protein truncating variants (Genetics in Medicine (2022) 24(1) (119–129), (S1098360021011308), (10.1016/j.gim.2021.08.016)) 17
Extended adjuvant endocrine treatment for premenopausal women: A Delphi approach to guide clinical practice 17
The central role of pathology labs in breast cancer precision oncology: a call for action 16
Vaccination against SARS-CoV-2 protects from morbidity, mortality and sequelae from COVID19 in patients with cancer 16
Working tables on Hormone Receptor positive (HR+), Human Epidermal growth factor Receptor 2 negative (HER2-) early stage breast cancer: Defining high risk of recurrence 16
SARS-CoV-2 omicron (B.1.1.529)-related COVID-19 sequelae in vaccinated and unvaccinated patients with cancer: results from the OnCovid registry 16
The Predictive Role of Radiomics in Breast Cancer Patients Imaged by [18F]FDG PET: Preliminary Results from a Prospective Cohort 16
i2b2 to optimize patients enrollment 15
Unveiling the Potential of Cyclin-Dependent Kinases 4 and 6 Inhibitors Beyond Progression in Hormone Receptor Positive/Human Epidermal Growth Factor Negative Advanced Breast Cancer – A Clinical Review 15
PARP-inhibitors for BRCA1/2-related advanced HER2-negative breast cancer: A meta-analysis and GRADE recommendations by the Italian Association of Medical Oncology 15
Prevalence and impact of COVID-19 sequelae on treatment and survival of patients with cancer who recovered from SARS-CoV-2 infection: evidence from the OnCovid retrospective, multicentre registry study 15
Clinical Review on the Management of Breast Cancer Visceral Crisis 15
The Role of Female Reproductive Hormones in the Association between Migraine and Breast Cancer: An Unanswered Question 15
Loco-Regional Treatment of the Primary Tumor in De Novo Metastatic Breast Cancer Patients Undergoing Front-Line Chemotherapy 15
Prospective observational study on the impact of the 21-gene assay on treatment decisions and resources optimization in breast cancer patients in Lombardy: The BONDX study 15
Pandemic Phase-Adjusted Analysis of COVID-19 Outcomes Reveals Reduced Intrinsic Vulnerability and Substantial Vaccine Protection From Severe Acute Respiratory Syndrome Coronavirus 2 in Patients With Breast Cancer 15
Multigene signatures for early breast cancer in clinical practice: A report of the Lombardy genomic assays for breast cancer working group 14
Corrigendum to “Optimizing choices and sequences in the diagnostic-therapeutic landscape of advanced triple-negative breast cancer: An Italian consensus paper and critical review” [Cancer Treatm. Rev. 114 (2023) 102511] (Cancer Treatment Reviews (2023) 114, (S0305737223000026), (10.1016/j.ctrv.2023.102511)) 14
Specialist palliative and end-of-life care for patients with cancer and SARS-CoV-2 infection: a European perspective 14
Acute respiratory distress syndrome after SARS-CoV-2 infection on young adult population: International observational federated study based on electronic health records through the 4CE consortium 14
Immunotherapy for HER2-Positive Breast Cancer: Clinical Evidence and Future Perspectives 14
HGF/c-met signalling in the tumor microenvironment 14
Hope and Hype around Immunotherapy in Triple-Negative Breast Cancer 14
Optimizing choices and sequences in the diagnostic-therapeutic landscape of advanced triple-negative breast cancer: An Italian consensus paper and critical review 13
Transforming Breast Cancer Care: Cutting-Edge Insights and Future Directions 13
Potential pitfalls in the use of real-world data for studying long COVID 13
Long-term survival in a fraction of patients with metastatic breast cancer who received consolidation therapy with high-dose chemotherapy and autologous stem cell transplant between 2000 and 2015: an EBMT registry-based study 13
Time-Dependent COVID-19 Mortality in Patients With Cancer: An Updated Analysis of the OnCovid Registry 13
Unlocking methodological insights on oncology efficacy endpoints: from statistical to clinical and vice versa. Letter to the editor regarding ‘Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2− advanced breast cancer: final overall survival results of MONARCH 3’ by M. P. Goetz et al 13
Corrigendum to “Optimizing choices and sequences in the diagnostic-therapeutic landscape of advanced triple-negative breast cancer: An Italian consensus paper and critical review” [Cancer Treat. Rev. 114 (2023) 102511] (Cancer Treatment Reviews (2023) 114, (S0305737223000026), (10.1016/j.ctrv.2023.102511)) 13
Heterogeneity of triple-negative breast cancer: understanding the Daedalian labyrinth and how it could reveal new drug targets 13
A Prognostic Model Based on Residual Cancer Burden and Tumor-Infiltrating Lymphocytes on Residual Disease after Neoadjuvant Therapy in HER2+ Breast Cancer 12
Randomized, open-label, phase II, biomarker study of immune-mediated mechanism of action of neoadjuvant subcutaneous trastuzumab in patients with locally advanced, inflammatory, or early HER2-positive breast cancer - Immun-HER trial (GOIRC-01-2016) 12
A Remote Monitoring System to Optimize the Home Management of Oral Anticancer Therapies (ONCO-TreC): Prospective Training-Validation Trial 12
COVID-19 in breast cancer patients: a subanalysis of the OnCovid registry 12
Long-term kidney function recovery and mortality after COVID-19-associated acute kidney injury: An international multi-centre observational cohort study 12
International electronic health record-derived COVID-19 clinical course profiles: the 4CE consortium 12
Systemic pro-inflammatory response identifies patients with cancer with adverse outcomes from SARS-CoV-2 infection: the OnCovid Inflammatory Score 12
What Every Reader Should Know About Studies Using Electronic Health Record Data but May Be Afraid to Ask 12
Unravelling the Epigenetic Code: DNA Methylation in Plants and Its Role in Stress Response 12
Totale 3.823
Salva come PNG Salva come JPEG
Categoria #
all - tutte 16.526
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 16.526
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202057 0 0 0 0 0 0 0 0 0 22 23 12
2020/2021368 11 27 29 32 23 22 18 37 35 49 21 64
2021/2022201 17 23 36 12 4 13 5 8 8 21 25 29
2022/2023357 35 123 36 22 22 49 0 22 22 1 15 10
2023/2024213 5 6 11 8 32 50 42 8 19 0 7 25
2024/20252.171 31 74 15 28 60 646 313 116 318 570 0 0
Totale 3.989